Screener
NeoGenomics NEO Common stock, par value (in dollars per share)
Common stock, par value (in dollars per share) at other companies
Other financials
Where this comes from
Reported directly by NeoGenomics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.
The source filing: NeoGenomics’s 10-Q, filed July 28, 2026.
- Filed
- Jul 28, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001077183-26-000059
| Line item | (unaudited)June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total liabilities | $566,511 | $523,268 |
| Commitments and contingencies (Note 12) | ||
| Stockholders’ equity | ||
| Common stock, $0.001 par value, (250,000,000 shares authorized; 130,301,168 and 128,989,152 shares issued, respectively; 127,917,946 and 128,989,152 shares outstanding, respectively) | $130 | $129 |
| Treasury stock, at cost, (2,383,222 and 0 shares, respectively) (Note 7) | (25,000) | — |
| Additional paid-in capital | 1,259,272 | 1,270,235 |
| Accumulated other comprehensive income | 4 | 4 |
| Accumulated deficit | (448,674) | (433,806) |
Item 1. Financial Statements (unaudited)
FAQ
- What is NeoGenomics's common stock, par value (in dollars per share)?
- NeoGenomics (NEO) reported common stock, par value (in dollars per share) of $0 in Q2 2026.
- How has NeoGenomics's common stock, par value (in dollars per share) changed year-over-year?
- NeoGenomics's common stock, par value (in dollars per share) decreased by 0.0% year-over-year, from $0 to $0.
Ask your AI about NeoGenomics's common stock, par value (in dollars per share).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude